Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- About
Biora Therapeutics, Inc. (BIORQ)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/05/2025: BIORQ (1-star) is a SELL. SELL since 3 days. Profits (-25.00%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
0 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
Analysis of Past Performance
Type Stock | Historic Profit -55.48% | Avg. Invested days 21 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/05/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 0.08 - 7.90 | Updated Date 05/29/2025 |
52 Weeks Range 0.08 - 7.90 | Updated Date 05/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating - |
Shares Outstanding - | Shares Floating - | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Biora Therapeutics, Inc.
Company Overview
History and Background
Biora Therapeutics, Inc. (formerly Progenity, Inc.) was founded in 2010. Initially focused on women's health diagnostics, it transitioned to developing targeted therapeutics for inflammatory bowel diseases (IBD) and other gastrointestinal (GI) conditions. The company has undergone several strategic shifts, including a name change to Biora Therapeutics, reflecting its focus on targeted therapeutics.
Core Business Areas
- Targeted Therapeutics Development: Biora focuses on developing oral biotherapeutics that can deliver drugs directly to the site of disease in the GI tract. Their lead program is focused on IBD.
- Drug Delivery Platform: The company is developing a proprietary ingestible device platform for targeted drug delivery. The device is designed to bypass the stomach and deliver drugs directly to the small intestine or colon.
Leadership and Structure
Adi Mohanty is the CEO. The company has a board of directors and a management team focused on drug development, engineering, and clinical operations.
Top Products and Market Share
Key Offerings
- Pill Camera Technology (legacy diagnostics): Progenity's legacy business was in diagnostics including prenatal testing and pill cameras. Pill Camera Technology is a capsule endoscopy system for visualizing the GI tract. Market share data not publicly available. Competitors include Medtronic, Given Imaging (acquired by Medtronic), Olympus.
- BT-003 (lead drug candidate for IBD): BT-003 is Biora's lead drug candidate. It is an oral biotherapeutic for the treatment of ulcerative colitis. The drug is in clinical development, so it is not revenue-generating. Competitors include AbbVie (Humira, Rinvoq), Takeda (Entyvio), Johnson & Johnson (Stelara).
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive, with significant investment in research and development. The IBD market is a large and growing market due to increasing prevalence of the disease and the availability of new therapies.
Positioning
Biora is focused on developing targeted oral biotherapeutics. They differentiate by utilizing a novel drug delivery platform that can potentially improve drug efficacy and reduce systemic side effects. They aim to compete in segments of the IBD treatment market.
Total Addressable Market (TAM)
The global inflammatory bowel disease (IBD) market is projected to reach approximately $25.7 billion by 2028. Biora is positioning itself to capture a portion of this market with its targeted oral biotherapeutics.
Upturn SWOT Analysis
Strengths
- Novel drug delivery platform
- Targeted therapeutic approach
- Experienced management team
- Potential for improved drug efficacy
Weaknesses
- Early stage clinical development
- High cash burn rate
- Reliance on successful clinical trials
- Limited financial resources
Opportunities
- Partnerships with pharmaceutical companies
- Expansion into new therapeutic areas
- Positive clinical trial results
- Increasing prevalence of IBD
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Patent challenges
- Economic downturn
Competitors and Market Share
Key Competitors
- ABBV
- TAK
- JNJ
Competitive Landscape
Biora faces intense competition from established pharmaceutical companies with greater resources and established products. Biora's advantage lies in its innovative targeted drug delivery platform. However, it is in an earlier stage of development compared to its competitors.
Major Acquisitions
Metrodora Institute
- Year: 2023
- Acquisition Price (USD millions): 5.4
- Strategic Rationale: Metrodora Institute's research will support Biora's efforts to more precisely target the delivery of therapeutic agents within the GI tract.
Growth Trajectory and Initiatives
Historical Growth: Historically, Biora's growth was focused on its diagnostics business. It has since shifted focus to biotherapeutics.
Future Projections: Future growth is highly dependent on the success of its clinical trials. Analyst projections vary widely. Positive clinical data is needed to achieve growth.
Recent Initiatives: Recent initiatives include advancing BT-003 into clinical trials, developing its oral biotherapeutics delivery platform, and securing partnerships.
Summary
Biora Therapeutics is a high-risk, high-reward company focused on developing targeted oral biotherapeutics for IBD using a novel drug delivery platform. Its success hinges on the outcome of clinical trials and its ability to secure partnerships. The company faces significant competition from larger, established pharmaceutical companies and requires substantial capital to fund its research and development activities. They recently made an acquisition that will help the company achieve their goals.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Company Website
- Analyst Reports
- Press Releases
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investors should conduct their own due diligence before making investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Biora Therapeutics, Inc.
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date - | CEO & Director Mr. Aditya P. Mohanty M.B.A. | ||
Sector - | Industry - | Full time employees 58 | |
Full time employees 58 | |||
Biora Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic oral delivery platform designs to replace injection with needle-free, oral delivery of large molecules for management of chronic diseases. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California. On May 27, 2025, the voluntary petition of Biora Therapeutics, Inc. for reorganization under Chapter 11 was converted to Chapter 7. It had filed for Chapter 11 bankruptcy on December 27, 2024.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.